Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Blackhall, Fiona; Jao, Kevin; Greillier, Laurent; Cho, Byoung; Penkov, Konstantin; Reguart, Noemi; Majem, Margarita; Nackaerts, Kristiaan; Syrigos, Konstantinos; Hansen, Karin; Schuette, Wolfgang; Cetnar, Jeremy; Cappuzzo, Federico; Okamoto, Isamu; ERMAN, MUSTAFA; Langer, Seppo; Kato, Terufumi; Groen, Harry; Sun, Zhaowen; Luo, Yan; Tanwani, Poonam; Caffrey, Laura; Komarnitsky, Philip; Reinmuth, Niels

doi:10.1016/j.jtho.2021.02.009

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Blackhall F., Jao K., Greillier L., Cho B. C., Penkov K., Reguart N., ...More

JOURNAL OF THORACIC ONCOLOGY, vol.16, no.9, pp.1547-1558, 2021 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 16 Issue: 9
Publication Date: 2021
Doi Number: 10.1016/j.jtho.2021.02.009
Journal Name: JOURNAL OF THORACIC ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Page Numbers: pp.1547-1558
Keywords: Small cell lung cancer, Rovalpituzumab tesirine, Delta-like protein 3, Topotecan, CELL LUNG-CANCER, DRUG
Open Archive Collection: AVESIS Open Access Collection
Hacettepe University Affiliated: Yes

Abstract

Introduction: DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. The efficacy and safety of Rova-T compared with topotecan as second-line therapy in patients with SCLC expressing high levels of DLL3 (DLL3-high) was evaluated.